In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies ...

mRNA vaccines achieved their first success against COVID-19, but could a bigger target be next? Ben Hargreaves examines whether the technology could provide a new tool against cancer, and how ...

Lipid nanoparticle (LNP) mRNA vaccines emerged during the COVID-19 pandemic to form an almost miraculous protection against a virus, which killed millions around the world. Aided by expedited ...

Moderna (MRNA) reachead $24.73 at the closing of the latest trading day, reflecting a -1.85% change compared to its last close. The Biden administration is reportedly in talks with vaccine makers ...

The technology behind Moderna’s COVID-19 vaccine — mRNA packaged in lipid nanoparticles — has the potential to reduce disparities in global health and help fight future pandemics.

Bin Wu, associate professor in the department of Biophysics and Biophysical Chemistry at the School of Medicine, visited ...

This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

本文研究揭开了mRNA疫苗效力背后的分子机制，强调了TENT5A在增强mRNA稳定性和免疫效力中的关键作用。 在抗击新冠疫情的全球战役中，mRNA疫苗以其 ...